Close

Immunogen (IMGN) Declines; Roche Reports Disappointing MARIANNE Trial Results

December 19, 2014 8:01 AM EST Send to a Friend
ImmunoGen, Inc.(NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login